A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy
Phase 3
1,328
about 4.8 years
12+
87 sites in AL, AR, AZ +25
About this study
Researchers are testing a treatment called upadacitinib for people with hidradenitis suppurativa who haven't responded to anti-TNF therapy. The trial will evaluate the safety and effectiveness of upadacitinib in reducing disease activity and monitoring adverse events. Participants will take either upadacitinib or a placebo daily for a period of time.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Placebo
- 2.Take Upadacitinib
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
upadacitinib
oral (Oral Solution)
Primary: Number of Participants with Adverse Events (AEs)
Secondary: Change from Baseline in Dermatology Life Quality Index (DLQI) for Adult Participants and Adolescent Participants Age ≥16 Years Old and Older, Change from Baseline in Draining Fistula Count, Change from Baseline in Hidradenitis Suppurativa (HS)-Related Odor, Based on Hidradenitis Suppurativa Symptom Assessment (HSSA) Question 8, Change from Baseline in Hidradenitis Suppurativa Impact Assessment (HSIA), Change from Baseline in Hidradenitis Suppurativa Symptom Assessment (HSSA), Change from Baseline in the Patient's Global Assessment of Hidradenitis Suppurativa (HS)-Related Skin Pain NRS, Percentage of Participants Achieving Numeric Rating Scale 30 (NRS30) at Week 4 Among Participants with NRS ≥ 3 at Baseline